Trifecta-Kidney cfDNA-MMDx Study
ConditionKidney Transplant Rejection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Alberta
About this trial
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Eligibility criteria
Qualifiers
All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.
Disqualifiers
Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.
Trial design
Treatments tested in this trial
- MMDx
- Prospera
- HLA antibody
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
31Australia
Department of Nephrology, The Royal Melbourne Hospital 1 South EastVIC 3050, Melbourne Australia
Canada
University of Alberta, Department of MedicineT6G 2G3, EdmontonAlberta, Canada
ST. Paul's Hospital, 6A Providence Building, 1081 Burrard StreetV6Z 1Y6, VancouverBritish Columbia, Canada
Croatia
University Hospital Merkur Renal Division1910000, Zagreb Croatia
Sponsors and collaborators
University of Alberta
Lead sponsor
Natera, Inc.
Collaborator
One Lambda
Collaborator
Source ClinicalTrials.gov